Breast Cancer

, Volume 24, Issue 2, pp 171–179

Systematic review of ixabepilone for treating metastatic breast cancer

Review Article

Abstract

Background

Ixabepilone is now a Food and Drug Administration-approved therapeutic option for patients with metastatic breast cancer (MBC) whose disease has progressed despite prior anthracycline and taxane therapy. We conducted a systematic review and meta-analysis to systematically evaluate the efficacy and safety of ixabepilone for treating metastatic breast cancer.

Methods

A systematic review and meta-analysis were conducted. Randomized controlled studies applying ixabepilone for treating MBC were included. The primary outcome was Overall Survival (OS). The authors of primary articles were contacted and methodological quality was evaluated. Subgroups were drawn based on intervention measures; heterogeneity and bias were discussed.

Results

Eight studies with 5247 patients were included. Compared with a weekly schedule, a triweekly schedule of ixabepilone was better at improving overall response rate (ORR), while there were no differences in improving OS and progression-free survival (PFS). Ixabepilone plus capecitabine was superior to capecitabine monotherapy in improving OS, PFS and ORR. Paclitaxel was more effective than ixabepilone in terms of OS and PFS. There was no difference in the improvement of ORR, clinical benefit rate (CBR) and disease control rate (DCR) between ixabepilone and eribulin.

Conclusions

Current evidence suggests that a triweekly schedule of ixabepilone is more effective than weekly dosing in improving ORR. Use of ixabepilone in combination with capecitabine possesses superior clinical efficacy to the use of capecitabine alone. Paclitaxel was more effective than ixabepilone in terms of OS and PFS. The efficacy and safety between ixabepilone and eribulin were identical.

Keywords

Metastatic breast cancer Therapy Systematic review Meta-analysis Ixabepilone 

References

  1. 1.
    Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reducecancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.CrossRefPubMedGoogle Scholar
  2. 2.
    Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999;17:485–93.PubMedGoogle Scholar
  3. 3.
    Fumoleau P, Largillier R, Clippe C, et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer. 2004;40:536–42.CrossRefPubMedGoogle Scholar
  4. 4.
    Altmann KH. Epothilone B and its analogs—a new family of anticancer agents. Mini Rev Med Chem. 2003;3:149–58.CrossRefPubMedGoogle Scholar
  5. 5.
    Lee F, Lewin A, Wen M, Ryseck R, Fargnoli J, Poruchynsky M, Fojo T, Mudenda B, Rugo H. Antiangiogenic (AG) synergywithixabepilone (ixa): translation of preclinical studies tothe clinical setting. Cancer Res. 2009;69:20.Google Scholar
  6. 6.
    Lee FY, Covello KL, Castaneda S, Hawken DR, Kan D, LewinA Wen ML, Ryseck RP, Fairchild CR, Fargnoli J, et al. Synergistic antitumor efficacy of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models. Clin Cancer Res. 2008;14:8123–31.CrossRefPubMedGoogle Scholar
  7. 7.
    Paradiso A, Mangia A, Chiriatti A, Tommasi S, Zito A, et al. Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol. 2005;16(Suppl 4):iv14–9.PubMedGoogle Scholar
  8. 8.
    Seve P, Isaac S, Tredan O, Souquet PJ, Pacheco Y, et al. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with nonsmall cell lung cancer receiving vinorelbine-based chemotherapy. Clinl Cancer Res. 2005;11:5481–6.CrossRefGoogle Scholar
  9. 9.
    Andreopoulou E, Muggia F. Pharmacodynamics of tubulin and tubulinbinding agents: extending their potential beyond taxanes. Clin Breast Cancer. 2008;8(Suppl 2):S54–60.CrossRefPubMedGoogle Scholar
  10. 10.
    Fountzilas G, Kotoula V, Pectasides D, Kouvatseas G, Timotheadou E, et al. Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial. PLoS One. 2013;8:e69256.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Rugo HS, Campone M, Amadori D, Wardley AM, Aldrighetti D, Conte PF, Liu D, Mudenda B, McHenry MB. Pivot XB (2013) A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer. Breast Cancer Res Treat. 2013;139:411–9.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Smith JW, Vukelja SJ, Rabe AC, et al. Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patients. Breast Cancer Res Treat. 2013;142:381–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Sparano JA, Vrdoljak E, Rixe O, Xu B, et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2010;28:3256–62.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25:5210–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Vahdat LT, Garcia AA, Vogel C, et al. Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy. Breast Cancer Res Treat. 2013;140:341–51.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Vahdat LT, Vrdoljak E, Gómezc H, et al. Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer. J Geriatr Oncol. 2013;4:346–52.CrossRefPubMedGoogle Scholar
  17. 17.
    Rugo HS, Barry WT, Aspitia AM, et al. Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer: CALGB40502/NCCTG N063H (Alliance). J Clin Oncol. 2015;33:2361–9.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Myers Squibb Company. IXEMPRA® (ixabepilone) prescribing information. Bristol-Myers Squibb Company, Princeton, NJ.Google Scholar
  19. 19.
    Moulder S, Li H, Wang M, Gradishar WJ, Perez EA, Sparano JA, Pins M, Yang X, Sledge GW. A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial. Breast Cancer Res Treat. 2010;119:663–71.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Rugo HS, Campone M, Amadori D, Wardley AM, Aldrighetti D, Conte PF, Liu D, Mudenda B, McHenry MB, Pivot XB. Randomized phase II study of weekly versus every 3 week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev(pac/bev) as first-line therapy for metastatic breast cancer (MBC): final results. J Clin Oncol. 2010;28(Suppl 15):1040.Google Scholar
  21. 21.
    Kossoff EB, Ngamphaiboon N, Laudico TJ, O’Connor TL. Weekly ixabepilone administration in heavily pretreated metastatic breast cancer patients. Med Oncol. 2011;28(Suppl 1):S115–20.CrossRefPubMedGoogle Scholar
  22. 22.
    Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel refractory metastatic breast cancer. J Clin Oncol. 1999;17:485–93.PubMedGoogle Scholar
  23. 23.
    Blum JL, Dees C, Chacko A, et al. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer. J Clin Oncol. 2006;24:4384–90.CrossRefPubMedGoogle Scholar
  24. 24.
    Talbot DC, Moiseyenko V, Van Belle S, et al. Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer. 2002;86:1367–72.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Kuznetsov G, Towle MJ, Cheng H, Kawamura T, TenDyke K, Liu D, Kishi Y, Yu MJ, Littlefield BA. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res. 2004;64:5760–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Towle MJ, Salvato KA, Budrow J, Wels BF, Kuznetsov G, Aalfs KK, Welsh S, Zheng W, Seletsky BM, Palme MH, Habgood GJ, Singer LA, Dipietro LV, Wang Y, Chen JJ, Quincy DA, Davis A, Yoshimatsu K, Kishi Y, Yu MJ, Littlefield BA. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 2001;61:1013–21.PubMedGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 2016

Authors and Affiliations

  1. 1.College of Pharmacy, Southwest University for NationalitiesChengduPeople’s Republic of China
  2. 2.Sichuan Industrial Institute of Antibiotics of Chengdu UniversityChengduPeople’s Republic of China

Personalised recommendations